CalciMedica’s (CALC) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of CalciMedica (NASDAQ:CALC) in a report issued on Thursday, Benzinga reports. The firm currently has a $20.00 price target on the stock.

Separately, Oppenheimer reaffirmed an outperform rating and issued a $14.00 price target on shares of CalciMedica in a research note on Monday, April 1st.

CalciMedica Price Performance

Shares of NASDAQ CALC opened at $3.15 on Thursday. The company has a market cap of $33.86 million, a P/E ratio of -1.47 and a beta of 1.35. The firm has a 50-day simple moving average of $5.27 and a two-hundred day simple moving average of $4.60. CalciMedica has a 1 year low of $1.75 and a 1 year high of $8.38.

CalciMedica (NASDAQ:CALC) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.07. As a group, equities research analysts expect that CalciMedica will post -2.05 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of CALC. BML Capital Management LLC lifted its holdings in shares of CalciMedica by 10.3% in the 1st quarter. BML Capital Management LLC now owns 160,424 shares of the company’s stock worth $667,000 after buying an additional 15,000 shares during the period. Meritage Portfolio Management grew its holdings in CalciMedica by 360.0% during the 4th quarter. Meritage Portfolio Management now owns 46,000 shares of the company’s stock worth $132,000 after acquiring an additional 36,000 shares in the last quarter. Finally, Hudson Bay Capital Management LP bought a new position in CalciMedica during the 3rd quarter worth about $432,000.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.